« Back

Treatment Licensed in US for People with Active Secondary Progressive MS

Fitted

Friday March 29 2019 11:06 AM

FDA approves the drug Siponimod, to treat people with active secondary progressive MS

The US Food and Drug Administration (FDA) has approved a new drug, siponimod, to treat MS.

The FDA decision approves the drug to be used for relapsing forms of MS, including for people with secondary progressive MS who continue to experience relapses (a phase described as active secondary progressive MS).

This follows successful trials showing that siponimod slowed disability progression and reduced inflammatory activity.

Siponimod is currently being reviewed by the European Medicines Agency (EMA), the body responsible for drug licensing in Europe. A decision is expected later this year.

Siponimod is an immune modulating drug, taken as a pill, once a day.

Professor Xavier Montalban, Chair of the International Medical and Scientific Board for MS International Federation, commented:

‘This is another important step in our efforts to make sure that all types of MS can be treated effectively.

‘Each new drug that is developed and approved not only gives us a new treatment option for people with MS; it helps us to understand MS better. Of course we still have much work to do, but piece by piece we are unravelling this disease and making strides towards our ultimate goal of stopping MS.’

In many countries, people with secondary progressive MS who still have signs of inflammatory activity can continue with existing treatments for relapsing MS. Siponimod’s approval by the FDA specifically applies to these people, as well as those with other forms of relapsing MS.

Some countries do not allow drugs that have been approved for relapsing MS to also be used to treat secondary progressive MS. Siponimod could provide a new treatment option for those living with active secondary progressive MS.

The clinical trials tested siponimod against placebo, not against other treatments. The largest (Phase 3) trial was conducted across 31 countries.  When enrolled into the study, trial participants had been living with MS for an average of 17 years, and had an average age of 48.

Read the FDA’s announcement here.

Author: MS International Federation (MSIF)

Tags: siponimod, fda, secondaryprogressivems

Comments

Patrice

Monday April 01 2019 18:07

Is this drug available in Ireland I am looking at changing my treatment as not agree with me.

MS Ireland

Wednesday April 03 2019 11:08

Dear Patrice,

Thank you for your enquiry.

Siponimod It is not yet available in Ireland
https://www.ms-society.ie/blog-articles/2327-

Add a comment

Your email address will not be published and will only be used by MS Ireland to contact you should there be an issue with your comment.

Please read our policy on making comments. Basically, respect other people’s view, use appropriate language and be nice! Comments are published between 9am and 5pm, Monday to Friday.

We ask this question to ensure that you are a real person, and not a computer adding information automatically.

By commenting, you are adhering to our Terms of use / Privacy

Latest News

More news

What's hot

Small_camera-photographer-yellow-photography

Enter our 2020 Calendar Competition!

Calling all budding photographers! Enter our competition to see YOUR photo in our new calendar!

Find out more

Events Calendar

» Our next Event

21 June 2019: Open coffee morning and information on MS and the Clare Branch, everybody welcome.

View all events

eNEWS SIGNUP

If you'd like to receive e-news updates from The Society please enter your email address below. If you want to know more about how we manage personal data then please see our privacy policy.

My local MSI

Map of MS Ireland's service areas South Mid West West Midlands South East North East North West North Dublin City and Fingal South West Dublin and Kildare South East Dublin and Wicklow